Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed 2015: Innovation Spotlight On Diabetes, Heart Failure Start-Ups

Executive Summary

Medtech start-ups continue to bring fresh ideas and new approaches to a market that is continually looking for better and cheaper treatment options. The device industry’s major trade association recently featured dozens of start-ups at its annual conference, and companies offering new solutions to battle chronic diseases were among the highlights.

You may also be interested in...



Diabetes Market Sees Advances In CGMs, Artificial Pancreas Systems, And Connectivity

The focus of the diabetes market is firmly on the development of an artificial pancreas, now within two or three years from becoming commercialized, and progress is going so well that several companies are in line to release a product. Meanwhile, digital health is increasingly playing a major role in diabetes care, and device manufacturers are investing in connectivity solutions to satisfy patient and consumer needs.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel